TYRA — Tyra Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1863127 ·
Last close
$28.55
Market Cap
$1.70B
52W High
$40.65
52W Low
$24.66
ADV30
825,477
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -41,998,000 | -39,305,000 | 412,040,000 | 84,955,000 | 24,465,000 |
| Dec 2025 | 0 | — | -36,516,000 | -33,834,000 | 282,609,000 | 77,387,000 | 23,432,000 |
| Sep 2025 | 0 | — | -32,944,000 | -29,868,000 | 301,851,000 | 61,951,000 | 21,342,000 |
| Jun 2025 | 0 | — | -31,452,000 | -28,098,000 | 321,499,000 | 98,490,000 | 19,352,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-102,255,000
Investing CF
$-79,807,000
Financing CF
$166,296,000
CapEx
$-215,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.18
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-410,563,000
Inventory
—
Receivables
—
ST Investments
$298,511,000
EBIT TTM
$-142,910,000
Pretax Income TTM
$-131,105,000
Interest Exp TTM
—
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -132,762,000 | -119,947,000 | 282,609,000 | 23,432,000 | — | -95,142,000 |
| Dec 2024 | 0 | -104,177,000 | -86,481,000 | 363,558,000 | 20,407,000 | — | -69,774,000 |
| Dec 2023 | 0 | -79,945,000 | -69,134,000 | 225,857,000 | 21,595,000 | — | -50,139,000 |
| Dec 2022 | 0 | -58,927,000 | -55,325,000 | 266,181,000 | 8,352,000 | — | -50,285,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.83
Max Pain — expiry 2026-09-18
max pain strike: $20.00 · spot: $28.55 · call oi: 2,975 · put oi: 3Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZYME | Zymeworks Inc. | $1.70B | $23.26 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $1.69B | $15.19 | — |
| PGEN | PRECIGEN, INC. | $1.71B | $4.80 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $1.67B | $116.51 | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.66B | $15.77 | — |
News headlines (Yahoo Finance, 1h cache)
Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?
2026-06-12 01:16 · Yahoo
Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says
2026-06-10 14:57 · Yahoo
Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)
2026-06-01 08:03 · Yahoo
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
2026-05-21 12:00 · Yahoo
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares
2026-05-17 19:01 · Yahoo
Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Momentum
2026-05-14 13:20 · Yahoo
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
2026-05-13 12:00 · Yahoo
Tyra Biosciences to Participate in Upcoming Investor Conferences
2026-05-07 20:05 · Yahoo
Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib
2026-04-24 13:42 · Yahoo
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
2026-04-17 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.